Product Name :
Bromfenac sodium hydrate
Description:
Bromfenac sodium hydrate (Bromfenac monosodium salt sesquihydrate) is a potent and orally active inhibitor of COX, with IC50s of 5.56 and 7.45 nM for COX-1 and COX-2, respectively. Bromfenac sodium hydrate is a brominated non-steroidal anti-inflammatory/analgesic drug (NSAID), and it is commonly used for the research of postoperative inflammation and pain following cataract surgery, and pseudophakic cystoid macular edema (CME).
CAS:
120638-55-3
Molecular Weight:
766.34
Formula:
C30H28Br2N2Na2O9
Chemical Name:
disodium bis(2-[2-amino-3-(4-bromobenzoyl)phenyl]acetate) trihydrate
Smiles :
O.O.O.[Na+].[Na+].NC1=C(C=CC=C1CC([O-])=O)C(=O)C1C=CC(Br)=CC=1.NC1=C(C=CC=C1CC([O-])=O)C(=O)C1C=CC(Br)=CC=1
InChiKey:
PPOSVVJOVKVBPW-UHFFFAOYSA-L
InChi :
InChI=1S/2C15H12BrNO3.2Na.3H2O/c2*16-11-6-4-9(5-7-11)15(20)12-3-1-2-10(14(12)17)8-13(18)19;;;;;/h2*1-7H,8,17H2,(H,18,19);;;3*1H2/q;;2*+1;;;/p-2
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.{{J14} medchemexpress|{J14} Reactive Oxygen Species|{J14} Protocol|{J14} Description|{J14} supplier|{J14} Autophagy}
Additional information:
Bromfenac sodium hydrate (Bromfenac monosodium salt sesquihydrate) is a potent and orally active inhibitor of COX, with IC50s of 5.{{Psoralen} web|{Psoralen} HIV|{Psoralen} Protocol|{Psoralen} Formula|{Psoralen} manufacturer|{Psoralen} Cancer} 56 and 7.45 nM for COX-1 and COX-2, respectively. Bromfenac sodium hydrate is a brominated non-steroidal anti-inflammatory/analgesic drug (NSAID), and it is commonly used for the research of postoperative inflammation and pain following cataract surgery, and pseudophakic cystoid macular edema (CME).|Product information|CAS Number: 120638-55-3|Molecular Weight: 766.PMID:32144889 34|Formula: C30H28Br2N2Na2O9|Chemical Name: disodium bis(2-[2-amino-3-(4-bromobenzoyl)phenyl]acetate) trihydrate|Smiles: O.O.O.[Na+].[Na+].NC1=C(C=CC=C1CC([O-])=O)C(=O)C1C=CC(Br)=CC=1.NC1=C(C=CC=C1CC([O-])=O)C(=O)C1C=CC(Br)=CC=1|InChiKey: PPOSVVJOVKVBPW-UHFFFAOYSA-L|InChi: InChI=1S/2C15H12BrNO3.2Na.3H2O/c2*16-11-6-4-9(5-7-11)15(20)12-3-1-2-10(14(12)17)8-13(18)19;;;;;/h2*1-7H,8,17H2,(H,18,19);;;3*1H2/q;;2*+1;;;/p-2|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : ≥ 100 mg/mL (260.98 mM). H2O : ≥ 100 mg/mL (260.98 mM).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|Bromfenac (90 μg/mL; 48 h) inhibits TGF-b1-induced extracellular matrix (ECM) synthesis and myofibroblast activation in HConFs and HPFs. Bromfenac (30-90 μg/mL; 48 h) decreases the protein and mRNA expression levels of FN, COL3, a-SMA, and survivin in a dose-dependent manner in HConFs and HPFs. Bromfenac (30-90 μg/mL; 48 h) declines the phosphorylated protein levels of AKT, ERK1/2, and GSK-3b-S9 with dosage in HPFs and HConFs.|In Vivo:|Bromfenac (0.0032-3.16%; 100 or 200 μL; rubbed onto the backs) produces significant anti-inflammatory activity at concentrations as low as 0.1% (4 h pretreatment time) or 0.32% (18h pretreatment time) in rats. Bromfenac (0.032-3.16%; 100 μL; rubbed onto the paws) produces dose-related anti-inflammatory activity in rats. Bromfenac (0.032-1.0%; 50 μL) is 26 times more potent than indomethacin in blocking the erythema when applied directly onto the skin area exposed to UV light in guinea pigs. Bromfenac (0.0032-0.1%; 50μL; rubbed onto the uninjected paw for 4 h per day and 5 days per week) produces a dose and time dependent reduction in the paw volume of both hind limbs in rats. Bromfenac (0.32%; 50μL; rubbed onto the abdomen) produces significant blockade of abdominal constriction to ACh challenge in mice.|Products are for research use only. Not for human use.|